December 1, 1999Journal of Clinical Oncology
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20⁺B-Cell Non-Hodgkin's Lymphoma
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial evaluates IDEC-Y2B8 radioimmunotherapy effectiveness in relapsed NHL, suggesting promising outpatient treatment.
Key Points
- This trial aims to assess the safety and efficacy of IDEC-Y2B8 radioimmunotherapy in patients with relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma.
- Multicenter phase I/II trial
- Patients received doses of IDEC-Y2B8 after unlabeled rituximab
- Evaluated maximum-tolerated dose and overall response rate.
- The maximum-tolerated dose of IDEC-Y2B8 was 0.4 mCi/kg
- Overall response rate was 67% (26% complete response, 41% partial response) in the intent-to-treat population
- Median time to disease progression in responders was 12.9+ months.
Cite This Study
Witzig et al. (1999) studied this question.